Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 36.

Journal Article

Ataseven, B., Rhiem, K., Staniczok, C., Heitz, F., Pauly, N., Moubarak, M., Concin, N., Traut, A., Schmutzler, R. and Harter, P. (2022). Prevalence and oncological outcome of patients with primary epithelial ovarian cancer (EOC) carrying gene mutations or variants of unknown signifikance (VUS) detected by germline gene panel testing. Geburtshilfe Frauenheilkd., 82 (10). S. E44 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804

Ataseven, B., Tripon, D., Schwameis, R., Harter, P., Rhiem, K., Schneider, S., Heikaus, S., Baert, T., Alesina, P., Heitz, F., Traut, A., Groeben, H. T., Schmutzler, R. and du Bois, A. (2021). Impact of BRCA1/2 Germline Status on intraperitoneal Tumor Distribution, Operability, and Incidence of postoperative Complications in Patients with epithelial Ovarian Cancer. Geburtshilfe Frauenheilkd., 81 (4). S. E2 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804

Bluemcke, B., Baasner, A., Hauke, J., Wappenschmidt, B., Hahnen, E. and Schmutzler, R. (2014). First experiences with the GS Junior 454 in molecular genetic analysis of patients with hereditary breast and ovarian cancer at the Center of Familial Breast and Ovarian Cancer, Cologne. Oncol. Res. Treat., 37. S. 22 - 23. BASEL: KARGER. ISSN 2296-5262

Bluemcke, B., Keupp, K., Larsen, M., Baasner, A., Waha, A., Versmold, B., Driesen, J., Buelow, L., Ernst, C., Wappenschmidt, B., Hahnen, E. and Schmutzler, R. (2018). NGS-based detection of copy number variations in hereditary breast- and ovarian cancer germline diagnostics. Eur. J. Hum. Genet., 26. S. 536 - 538. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5438

Bosse, Autoren K., Faust, U., Gruber, I, Habhab, W., Guenther, G., Siebers-Renelt, U., Kiechle, M., Speiser, D., Dikow, N., Kast, K., Arnold, N., Vesper, A-S, Harbeck, N., Briest, S., Thomssen, C., Gehrig, A., Wallaschek, H., Solbach, C., Wolf, M., Witzel, I, Holzhauser, I, Kaulfuss, S., Janni, W., Engel, C., Riess, O., Schmutzler, R. and Schroeder, C. (2020). Clinical-pathological Characterization of 1078 Advice Seekers with pathogenic CHEK2 Mutation from the German Consortium of Familial Breast and Ovarian Cancer (DK-FBREK). Geburtshilfe Frauenheilkd., 80 (6). S. E23 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804

Buelow, L., Keupp, K., Richters, L., Pohl, E., Wappenschmidt, B., Zarghooni, V., Reichstein-Gnielinski, S., Maringa, M., Giesecke, J., Rhiem, K., Hahnen, E. and Schmutzler, R. (2017). Low-level gonosomal mosaicism of a de novo BRCA1 gene mutation - The origin of a constitutional mutation in a breast cancer family. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Danner, M., Mueller, D., Schmutzler, R., Rhiem, K., Engel, C., Stollenwerk, B., Stock, S. and Wassermann, K. (2016). ECONOMIC MODELING OF RISK-ADAPTED SCREEN-AND-TREAT STRATEGIES IN WOMEN AT HIGH-RISK FOR BREAST OR OVARIAN CANCER. Value Health, 19 (7). S. A737 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1524-4733

Dukatz, R., Halle, M., Engel, C., Berling, A., Hebestreit, K., Bischoff, S., Pfeifer, K., Grill, S., Yahiaoui-Doktor, M., Enders, U., Siniatchkin, M., Gerber, D., Bridstrup, J., Erickson, N., Loeffler, M., Meindl, A., Rhiem, K., Schmutzler, R. and Kiechle, M. (2016). Feasibility assessment on a lifestyle intervention in healthy and diseased BRCA 1/2 mutation carriers. Oncol. Res. Treat., 39. S. 59 - 60. BASEL: KARGER. ISSN 2296-5262

Eccles, D. M., Mitchell, G., Monteiro, A. N. A., Schmutzler, R., Couch, F. J., Spurdle, A. B. and Gomez-Garcia, E. B. (2015). BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. Ann. Oncol., 26 (10). S. 2057 - 2066. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Emons, G., Schmutzler, R. and Kiechle, M. (2020). 150th Birthday of the Archives of Gynecology and Obstetrics. Gynakologe, 53 (11). S. 725 - 726. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0393

Fischer, C., Engel, C., Sutter, C., Zachariae, S., Schmutzler, R., Meindl, A., Heidemann, S., Grimm, T., Goecke, T. O., Debatin, I., Horn, D., Wieacker, P., Gadzicki, D., Becker, K., Schaefer, D., Stock, F. and Voigtlaender, T. (2012). BRCA1/2 testing: uptake, phenocopies, and strategies to improve detection rates in initially negative families. Clin. Genet., 82 (5). S. 478 - 484. HOBOKEN: WILEY. ISSN 1399-0004

Geyer, C. E., Jr., Garber, J. E., Gelber, R. D., Yothers, G., Taboada, M., Ross, L., Rastogi, P., Cui, K., Arahmani, A., Aktan, G., Armstrong, A. C., Arnedos, M., Balmana, J., Bergh, J., Bliss, J., Delaloge, S., Domchek, S. M., Eisen, A., Elsafy, F., Fein, L. E., Fielding, A., Ford, J. M., Friedman, S., Gelmon, K. A., Gianni, L., Gnant, M., Hollingsworth, S. J., Im, S-A, Jager, A., Lakhani, S. R., Janni, W., Linderholm, B., Liu, T-W, Loman, N., Korde, L., Loibl, S., Lucas, P. C., Marme, F., de Duenas, E. Martinez, McConnell, R., Phillips, K-A, Piccart, M., Rossi, G., Schmutzler, R., Senkus, E., Shao, Z., Sharma, P., Singer, C. F., Spanic, T., Stickeler, E., Toi, M., Traina, T. A., Viale, G., Zoppoli, G., Park, Y. H., Yerushalmi, R., Yang, H., Pang, D., Jung, K. H., Mailliez, A., Fan, Z., Tennevet, I, Zhang, J., Nagy, T., Sonke, G. S., Sun, Q., Parton, M., Colleoni, M. A., Schmidt, M., Brufsky, A. M., Razaq, W., Kaufman, B., Cameron, D., Campbell, C., Tutt, A. N. J. and Johannsson, O. Th (2022). Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann. Oncol., 33 (12). S. 1250 - 1269. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Habhab, W., Faust, U., Guenther, G., Siebers-Renelt, U., Kiechle, M., Ott, C., Dikow, N., Kast, K., Vesper, A., Solbach, C., Harbeck, N., Stiller, M., Gehrig, A., Thomssen, C., Wallaschek, H., Arnold, N., Holzhauser, I., Kaulfuss, S., Volk, A., Janni, W., Engel, C., Schmutzler, R., Riess, O., Schroeder, C. and Bosse, K. (2020). Clinical and molecular characterization of 1253 carriers of a deleterious CHEK2 mutation from the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Eur. J. Hum. Genet., 28 (SUPPL 1). S. 93 - 95. LONDON: SPRINGERNATURE. ISSN 1476-5438

Harter, P., Baumann, K., Heimbach, A., Reuss, A., Jackisch, C., Hauke, J., Park-Simon, T. W., Richters, L., Hanker, L., Kroeber, S., Pfisterer, J., Gevensleben, H., Schnelzer, A., Dietrich, D., Schneider, S., Kommoss, S., Marme, F., Prieske, K., Schmutzler, R. and Hahnen, E. (2016). Mutations of risk genes for ovarian cancer in consecutive ovarian cancer patients (AGO TR-1 study). Int. J. Gynecol. Cancer, 26. S. 81 - 83. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1525-1438

Hauke, J., Becker, A., Schnurbein, G., Neidhardt, G., Weber-Lassalle, N., Wappenschmidt, B., Hahnen, E., Meindl, A. and Schmutzler, R. (2014). RAD51C deletion screening identifies a recurrent gross deletion in breast and ovarian cancer families. Oncol. Res. Treat., 37. S. 96 - 97. BASEL: KARGER. ISSN 2296-5262

Heimbach, A., Hauke, J., Richters, L., Kroeber, S., Altmueller, J., Becker, C., Thiele, H., Nuernberg, P., Bluemcke, B., Neidhardt, G., Riehm, K., Schmutzler, R. and Hahnen, E. (2016). TruRisk (R) based next-generation sequencing reveals a high prevalence of deleterious ATM mutations in BRCA1/2-negative breast and ovarian cancer families. Oncol. Res. Treat., 39. S. 52 - 53. BASEL: KARGER. ISSN 2296-5262

Heitz, F., Ataseven, B., Moubarak, M., Staniczok, C., Schmutzler, R., Schameis, R., Heikaus, S., Concin, N., Riehm, K., Denkert, C. and Harter, P. (2022). HRD Testing and BRCA1/2 Germline Testing in Routine Clinical Practice in Patients with primary Ovarian Cancer. Geburtshilfe Frauenheilkd., 82 (10). S. E86 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804

Herold, N., Bredow, K., Hahnen, E., Wappenschmidt, B., Hauke, J., Wiedemann, R., Waha, A., Bluemcke, B., Pohl-Rescigno, E., Portnicki, M., Rhiem, K. and Schmutzler, R. (2020). Implementation of an educational program and risk-adjusted prevention program for breast and ovarian cancer of the German Consortium for Hereditary Breast- and Ovarian Cancer. Geburtshilfe Frauenheilkd., 80 (6). S. E37 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804

Herold, N., Bredow, K., Hahnen, E., Wappenschmidt, B., Hauke, J., Wiedemann, R., Waha, A., Bluemcke, B., Portnicki, M., Pohl-Rescigno, E., Rhiem, K., Kast, K., Huebbel, V, Maringa, M., Crombach, G. and Schmutzler, R. (2020). Knowledge-generating Care using the Example of hereditary Breast- and Ovarian Cancer (BC/OC): Evaluation of the comprehensive Care Concept. Geburtshilfe Frauenheilkd., 80 (10). S. E212 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804

Imterat, M., du Bois, A., Harter, P., Rhiem, K., Heitz, F., Concin, N., Traut, A., Schmutzler, R. and Ataseven, B. (2022). Incidence and prognostic impact of pathogenic germline mutations in gene panel testing of primary advanced epithelial ovarian cancer patients. Geburtshilfe Frauenheilkd., 82 (10). S. E97 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804

Isselhard, A., Toepper, M., Berger-Hoeger, B., Steckelberg, A., Fischer, H., Vitinius, F., Beifus, K., Koeberlein-Neu, J., Wiedemann, R., Rhiem, K., Schmutzler, R. and Stock, S. (2020). Implementation and evaluation of a nurse-led decision-coaching program for healthy breast cancer susceptibility gene (BRCA1/2) mutation carriers: a study protocol for the randomized controlled EDCP-BRCA study. Trials, 21 (1). LONDON: BMC. ISSN 1745-6215

Keupp, K., Ernst, C., Bluemcke, B., Versmold, B., Waha, A., Driesen, J., Baasner, A., Larsen, M., Buelow, L., Kroeber, S., Altmueller, J., Thiele, H., Nuernberg, P., Wappenschmidt, B., Neidhardt, G., Rhiem, K., Schmutzler, R., Hahnen, E. and Hauke, J. (2018). Next-generation sequencing via TruRisk (R) genepanel reveal high mutation prevalence in additional risk genes in German BRCA1/2-negative breast and ovarian cancer families. Eur. J. Hum. Genet., 26. S. 541 - 543. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5438

Keupp, K., Richters, L., Buelow, L., Kroeber, S., Ernst, C., Bluemcke, B., Versmold, B., Waha, A., Driesen, J., Baasner, A., Altmueller, J., Thiele, H., Nuernberg, P., Wappenschmidt, B., Neidhardt, G., Rhiem, K., Schmutzler, R., Hahnen, E. and Hauke, J. (2017). TruRisk (R) based next-generation sequencing in BRCA1/2-negative breast and ovarian cancer families reveal high mutation prevalence in additional risk genes. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Larsen, M., Bluemcke, J., Bluemcke, B., Ernst, C., Keupp, K., Buelow, L., Altmueller, J., Thiele, H., Nuernberg, P., Hahnen, E. and Schmutzler, R. (2018). Association of MUTYH with familial breast and ovarian cancer. Eur. J. Hum. Genet., 26. S. 540 - 541. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5438

Loibl, S., Weber, K. E., Timms, K. M., Elkin, E. P., Hahnen, E., Fasching, P. A., Lederer, B., Denkert, C., Schneeweiss, A., Braun, S., Salat, C. T., Rezai, M., Blohmer, J. U., Zahm, D. M., Jackisch, C., Gerber, B., Klare, P., Kuemmel, S., Schem, C., Paepke, S., Schmutzler, R., Rhiem, K., Penn, S., Reid, J., Nekljudova, V., Hartman, A-R, von Minckwitz, G. and Untch, M. (2018). Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann. Oncol., 29 (12). S. 2341 - 2348. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Marme, F., Harter, P., Hauke, J., Heitz, F., Reuss, A., Kommoss, S., Heimbach, A., Prieske, K., Richters, L., Burges, A., Neidhardt, G., de Gregorio, N., El-Balat, A., Hilpert, F., Meier, W., Heubner, M., Kast, K., Braicu, I., Hahnen, E. and Schmutzler, R. (2016). Incidence of germline mutations in risk genes including BRCA1/2 in consecutive ovarian cancer (OC) patients (AGO TR-1). Int. J. Gynecol. Cancer, 26. S. 194 - 196. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1525-1438

Pohl, E., Borde, J., Hauke, J., Schmidt, S., Weber-Lassalle, K., Ernst, C., Niederacher, D., Arnold, N., Hellebrand, H., Meindl, A., Gehrig, A., Schmidt, G., Dutrannoy, V., Kast, K., Hahnen, E. and Schmutzler, R. (2018). Beyond CHEK2 in breast cancer: Search for additional moderately penetrant risk gene variants by analyzing the oligogenic disease course in CHEK2 mutation carriers. Eur. J. Hum. Genet., 26. S. 535 - 537. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5438

Puppe, J., Brambillasca, C., Ratz, L., Bartke, L., van de Ven, M., Bouwman, P., van Tellingen, O., Isensee, J., Hucho, T., van Lohuizen, M., Malter, W., Schmutzler, R., Mallmann, P., Jonkers, J. and Reinhardt, C. (2020). Dual inhibition of EZH2 and ATM displays synergistic cytotoxicity in BRCA1-deficient breast. Geburtshilfe Frauenheilkd., 80 (10). S. E104 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804

Puppe, J., Liu, X., Ratz, L., Bartke, L., van de Ven, M., Vliet, M. H., Wientjes, E., van der Gulden, H., Zevenhoven, J., Hahnen, E., Malter, W., Wessels, L. F. A., Schmutzler, R., Mallmann, P., Reinhardt, C., Linn, S. and Jonkers, J. (2020). Double BRCA1 and BRCA2 inactivation is epistatic in mammary tumorigenesis and treatment response to PARP-inhibition and platinum drugs. Geburtshilfe Frauenheilkd., 80 (10). S. E104 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804

Rhiem, K., Herold, N., Bongartz, R., Schellong, G. and Schmutzler, R. (2014). Breast Cancer in young women after radiation therapy of Hodgkin disease in childhood and adolescence - individual therapeutic strategies. Oncol. Res. Treat., 37. S. 21 - 22. BASEL: KARGER. ISSN 2296-5262

Rhiem, K., Richters, L., Hahnen, E., Lampe, B., Rezai, M., Goehring, U. -J., Schumacher, C., Kuemmel, S., Ataseven, B. and Schmutzler, R. (2016). Benchmarking of the DKG check list for inclusion criteria of BRCA testing. Oncol. Res. Treat., 39. S. 59 - 60. BASEL: KARGER. ISSN 2296-5262

Richters, L., Rhiem, K., Wappenschmidt, B., Kiechle, M. and Schmutzler, R. (2014). Pathological complete response rates in patients with BRCA1/2-associated breast cancer after neoadjuvant chemotherapy. Oncol. Res. Treat., 37. S. 13 - 15. BASEL: KARGER. ISSN 2296-5262

Van den Bulcke, M., Boccia, S., de Censi, A., Decoster, L., Frederici, A., Kholmanskikh, O., Nowak, F., Peeters, M., Rolfo, C., Schmutzler, R., Salgado, R. and Vermeesch, J. (2016). Public Health Genomics in Cancer. Eur. J. Public Health, 26. OXFORD: OXFORD UNIV PRESS. ISSN 1464-360X

Wassermann, K., Rhiem, K. and Schmutzler, R. (2014). Psychosocial Factors Relating to the Decision Against or in Favour for Prophylactic Surgery. Oncol. Res. Treat., 37. S. 111 - 112. BASEL: KARGER. ISSN 2296-5262

von Mallek, D., Schmutzler, R., Hoeller, U., Just, K., Hermes, U. and Stingl, J. (2016). Pharmacogenetics of BRCA variants: Vulnerability to longterm adverse effects of chemotherapy or radiation in cancer patients. Oncol. Res. Treat., 39. S. 169 - 170. BASEL: KARGER. ISSN 2296-5262

von Minckwitz, G., Timms, K., Untch, M., Elkin, E. P., Hahnen, E., Fasching, P. A., Schneeweiss, A., Salat, C. T., Rezai, M., Blohmer, J-U, Zahm, D-M, Jackisch, C., Gerber, B., Klare, P., Kummel, S., Paepke, S., Schmutzler, R., Chau, S., Reid, J., Hartman, A-R, Nekljudova, V., Weber, K. E. and Loibl, S. (2017). Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

This list was generated on Fri Mar 29 12:27:38 2024 CET.